These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35668260)

  • 1. Environmental commitment of large US publicly traded companies producing healthcare equipment: a cross-sectional comparative study.
    Castagnini F; Castagnini L; Donati D; Traina F
    Environ Sci Pollut Res Int; 2022 Oct; 29(50):76158-76165. PubMed ID: 35668260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and compensation of academic leaders, professors, and trustees on publicly traded US healthcare company boards of directors: cross sectional study.
    Anderson TS; Good CB; Gellad WF
    BMJ; 2015 Sep; 351():h4826. PubMed ID: 26420786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Environmental Sustainability and Corporate Social Responsibility Reporting by Large Health Care Organizations.
    Senay E; Landrigan PJ
    JAMA Netw Open; 2018 Aug; 1(4):e180975. PubMed ID: 30646093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental sustainability disclosures in annual reports of mining companies listed on the Australian Stock Exchange (ASX).
    Miklosik A; Evans N
    Heliyon; 2021 Jul; 7(7):e07505. PubMed ID: 34296012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional analysis of reported corporate environmental sustainability practices.
    Cowan DM; Dopart P; Ferracini T; Sahmel J; Merryman K; Gaffney S; Paustenbach DJ
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):524-38. PubMed ID: 20850490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the Global Sustainability of the Korean Construction Industry Based on the GRI Standards.
    Park E; Kim Y; Lee A; Kim J; Kong H
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Mandatory Non-Financial Reporting of Romanian Companies in the Circular Economy Context.
    Hategan CD; Pitorac RI; Milu ND
    Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.
    Lexchin J; Batt S; Goldberg D; Shnier A
    BMJ Open; 2022 Mar; 12(3):e055287. PubMed ID: 35264357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Content Analysis of the Corporate Social Responsibility Practices of 9 Major Cannabis Companies in Canada and the US.
    Wakefield T; Glantz SA; Apollonio DE
    JAMA Netw Open; 2022 Aug; 5(8):e2228088. PubMed ID: 35997980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Servitization and sustainability actions. Evidence from European manufacturing companies.
    Doni F; Corvino A; Bianchi Martini S
    J Environ Manage; 2019 Mar; 234():367-378. PubMed ID: 30639860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Effect of Dynamic Capabilities on the ESG Reporting and Corporate Performance Relationship With Topic Modeling: Evidence From Global Companies.
    Yang BM; Yang OS
    Front Psychol; 2022; 13():898935. PubMed ID: 35645900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of voluntary carbon disclosure in the corporate real estate sector of Malaysia.
    Kalu JU; Buang A; Aliagha GU
    J Environ Manage; 2016 Nov; 182():519-524. PubMed ID: 27529312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of corporate sustainability reporting tools (SRTs).
    Siew RY
    J Environ Manage; 2015 Dec; 164():180-95. PubMed ID: 26379255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare in a carbon-constrained world.
    Charlesworth KE; Jamieson M
    Aust Health Rev; 2019 Jul; 43(3):241-245. PubMed ID: 29731002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational health and safety of multinational construction companies through evaluation of corporate social responsibility reports.
    Mavroulidis M; Vouros P; Fotiadis S; Konstantakopoulou F; Fountoulakis G; Nikolaou I; Evangelinos K
    J Safety Res; 2022 Jun; 81():45-54. PubMed ID: 35589305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the stated policies of prominent food companies related to obesity and non-communicable disease (NCD) prevention in Thailand.
    Cetthakrikul N; Phulkerd S; Jaichuen N; Sacks G; Tangcharoensathien V
    Global Health; 2019 Feb; 15(1):12. PubMed ID: 30764855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESG risks and corporate survival.
    Cohen G
    Environ Syst Decis; 2023; 43(1):16-21. PubMed ID: 36466558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.